Interventional closure of the left atrial appendage for stroke prevention: Experience of a high-volume center

Circulation Journal

Volumn 78, Issue 3, 2014, Pages 619-624

  Matsuo, Yae ^a,c   Sandri, Marcus ^a,c   Mangner, Norman ^a   Majunke, Nicolas ^a   Dähnert, Ingo ^a   Schuler, Gerhard ^a   Kurabayashi, Masahiko ^a   Möbius Winkler, Sven ^a,b,c  

^a UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^b Asklepios Klinik Weißenfels   (Germany)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Left atrial appendage; Stroke prevention; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; HEPARIN; WARFARIN;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEATH; FEMALE; FLUOROSCOPY; FOLLOW UP; GUIDE WIRE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; IMPLANTATION; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ATRIAL FIBRILLATION; HEART CATHETERIZATION; RETROSPECTIVE STUDY; STROKE; SURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE;

EID: 84894476415     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0828     Document Type: Article

References (29)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988
2. Sherman DG, Goldman L, Whiting RB, Jurgensen K, Kaste M, Easton JD. Thromboembolism in patients with atrial fibrillation. Arch Neurol 1984; 41: 708-710
3. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-107
4. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART- 2 Investigators. Trend of Westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. Circ J 2011; 75: 823-833
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford M. Validation of clinical classification schemes for predicting stroke Results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864-2870
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 236-272
7. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46
8. Oake N, Fergusson DA, Forster AJ, Walraven C. Frequency of adverse events in patients with poor anticoagulation: A meta-analysis. Can Med Assoc J 2007; 176: 1589-1594
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
12. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759
13. Sick PB, Schuler G, Hauptmann KE, Grube E, Yakubov S, Turi ZG, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007; 49: 1490-1495
14. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: Results from the Watchman left appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 2011; 123: 417-424
15. Möbius-Winkler S, Sandri M, Mangner N, Lurz P, Dähnert I, Schuler G. The WATCHMAN left atrial appendage closure device for atrial fibrillation. J Vis Exp 2012; 60: e3671, doi:10.3791/3671
16. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
17. Chue CD, Giovanni JD, Steeds RP. The role of echocardiography in percutaneous left atrial appendage occlusion. Eur J Echocardiogr 2011; 12: i3-i10
18. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to trevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
19. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation: The Framingham study. Stroke 1996; 27: 1760-1764
20. Banerjee A, Marin F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: Focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke 2011; 42: 3316-3322
21. Tendera M, Syzdół M, Parma Z. ARISTOLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012; 19: 4-10
22. Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, et al. Antithrombotic therapy in atrial fibrillation: Evaluation and positioning of new oral anticoagulant agents. Circ J 2011; 75: 1539-1547
23. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315
24. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxavan vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. Circ J 2012; 76: 2104-2111
25. Hori M, Connolly SJ, Zhu J, Liu LS, Lau C, Pais P, et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-1896
26. Reddy V, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with contraindication for oral anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013; 61: 2551-2556
27. Okura H, Inoue H, Tomon M, Nishiyama S, Yoshikawa T, Yoshida K. Is the left atrium the only embolic source in ischemic stroke patients with nonvalvular atrial fibrillation? Am J Cardiol 1999; 84: 1259-1261
28. Guazzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart 2009; 95: 102-106
29. Whitlock RP, Healey JS, Connolly SJ. Does left atrial appendage occlusion eliminate the need for warfarin? Circulation 2009; 120: 1927-1932.